(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 2.27% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Teva Pharmaceutical Industries's revenue in 2025 is $16,544,000,000.On average, 4 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,548,252,054,151, with the lowest TEVA revenue forecast at $19,369,570,415,151, and the highest TEVA revenue forecast at $19,690,356,057,043. On average, 5 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,616,153,117,880, with the lowest TEVA revenue forecast at $19,177,747,585,746, and the highest TEVA revenue forecast at $20,098,594,677,017.
In 2027, TEVA is forecast to generate $20,134,843,499,905 in revenue, with the lowest revenue forecast at $19,242,603,158,757 and the highest revenue forecast at $20,886,442,490,069.